Heart Failure

The FDA has approved the Optimizer Smart system as an implantable treatment option for heart failure patients with left ventricular ejection fraction between 25 and 45 percent who aren’t candidates for cardiac resynchronization therapy (CRT).

Researchers from the Rochester Institute of Technology are leveraging “natural processes” to provide insights into heart health with a toilet seat-based cardiovascular monitoring system.

A post-FDA approval study of Abbott’s CardioMEMS heart failure sensor found the device reduced HF-related hospitalizations by 58 percent in a trial group of 1,200 patients, researchers reported at this year’s American College of Cardiology symposium in New Orleans.

A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.

The FDA has expanded the indication for the MitraClip to include heart failure patients with moderate-to-severe secondary mitral regurgitation, the agency announced March 14. Abbott’s transcatheter mitral valve repair device was approved in 2013, but only for primary mitral regurgitation.

The FDA fast-tracked the approval process for a new generic valsartan product (Diovan) amid an ongoing shortage of the blood pressure and heart failure medication.

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

Even though the Hospital Readmission Reduction Program (HRRP) targeted principal heart failure admissions, a new analysis in the Journal of the American College of Cardiology showed readmissions also declined for patients with a secondary diagnosis of heart failure.

By the time three transplant physicians approached Tom Giangiulio Jr. about being the first patient in a new clinical trial to accept a heart from a Hepatitis C-positive donor, Giangiulio didn’t have much of a choice.

One in six patients with heart failure with reduced ejection fraction (HFrEF) develops worsening HF within 18 months of an initial diagnosis, according to research published in the Journal of the American College of Cardiology, and these declining patients aren’t receiving the right standard of care.

Nearly half of patients with heart failure (HF) take at least 10 medications per day, according to research published in the American Journal of Cardiology, yet an overwhelming 85 percent report willingness to add more drugs to that regimen if it helps them prevent further health events.

A nurse navigator-led program at Providence St. Vincent Medical Center in Oregon helped the hospital double its palliative care referral rates for advanced heart failure patients considered to be at high risk of readmission.